370 related articles for article (PubMed ID: 34417822)
21. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.
Behringer K; Thielen I; Mueller H; Goergen H; Eibl AD; Rosenbrock J; Halbsguth T; Eichenauer DA; Fuchs M; Reiners KS; Renno JH; van der Ven K; Kuehr M; von Wolff M; Diehl V; Engert A; Borchmann P
Ann Oncol; 2012 Jul; 23(7):1818-25. PubMed ID: 22228451
[TBL] [Abstract][Full Text] [Related]
22. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
[TBL] [Abstract][Full Text] [Related]
23. Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.
Zawati I; Adouni O; Finetti P; Manai M; Manai M; Gamoudi A; Birnbaum D; Bertucci F; Mezlini A
Cancer Radiother; 2020 Jun; 24(3):206-214. PubMed ID: 32171674
[TBL] [Abstract][Full Text] [Related]
24. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
[TBL] [Abstract][Full Text] [Related]
25. Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin's disease.
Ciccarone M; Cavaceppi P; Tesei C; Brunetti S; Pulsoni A; Annibali O; Gasparoli C; Battistini R; Hohaus S; Pelliccia S; Tafuri A; Cox MC; Cantonetti M; Rigacci L; Abruzzese E
Front Oncol; 2023; 13():1059393. PubMed ID: 37152067
[TBL] [Abstract][Full Text] [Related]
26. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study.
Tzeng CR; Huang Z; Asada Y; Zhang C; Ho MT; Li RHW; Kim JH; Govindarajan M; Vuyavanich T; Sini I; Wong PS; Singh S; Lin WY; Ho NT
Hum Reprod; 2023 Jul; 38(7):1368-1378. PubMed ID: 37105234
[TBL] [Abstract][Full Text] [Related]
28. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease.
Azem F; Samara N; Cohen T; Ben-Yosef D; Almog B; Lessing JB; Goor O; Amit A
J Assist Reprod Genet; 2008; 25(11-12):535-8. PubMed ID: 19015974
[TBL] [Abstract][Full Text] [Related]
29. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
30. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study.
Rosendahl M; Andersen CY; Ernst E; Westergaard LG; Rasmussen PE; Loft A; Andersen AN
Hum Reprod; 2008 Nov; 23(11):2475-83. PubMed ID: 18635528
[TBL] [Abstract][Full Text] [Related]
31. The effect of Covid-19 mRNA vaccine on serum anti-Müllerian hormone levels.
Mohr-Sasson A; Haas J; Abuhasira S; Sivan M; Doitch Amdurski H; Dadon T; Blumenfeld S; Derazne E; Hemi R; Orvieto R; Afek A; Rabinovici J
Hum Reprod; 2022 Mar; 37(3):534-541. PubMed ID: 34935913
[TBL] [Abstract][Full Text] [Related]
32. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
[TBL] [Abstract][Full Text] [Related]
33. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
[TBL] [Abstract][Full Text] [Related]
34. Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India.
Nayak L; Jain H; Bonda A; Epari S; Laskar S; Gokarn A; Shet T; Gujral S; Khanna N; Bagal B; Punatar S; Goda J; Thorat J; Rengaraj K; Sengar M
J Adolesc Young Adult Oncol; 2021 Oct; 10(5):581-587. PubMed ID: 33090916
[No Abstract] [Full Text] [Related]
35. Anti-Müllerian Hormone in Female Adolescent Cancer Patients Before, During, and After Completion of Therapy: A Pilot Feasibility Study.
Gupta AA; Lee Chong A; Deveault C; Traubici J; Maloney AM; Knight S; Lorenzo A; Allen L
J Pediatr Adolesc Gynecol; 2016 Dec; 29(6):599-603. PubMed ID: 27184535
[TBL] [Abstract][Full Text] [Related]
36. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
[TBL] [Abstract][Full Text] [Related]
38. Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
Demeestere I; Racape J; Dechene J; Dupuis J; Morschhauser F; De Wilde V; Lazarovici J; Ghesquieres H; Touati M; Sibon D; Alexis M; Gac AC; Moatti H; Virelizier E; Maisonneuve H; Pranger D; Houot R; Fornecker LM; Tempescul A; André M; Casasnovas RO
J Clin Oncol; 2021 Oct; 39(29):3251-3260. PubMed ID: 34156881
[TBL] [Abstract][Full Text] [Related]
39. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis.
Lie Fong S; Laven JSE; Duhamel A; Dewailly D
Hum Reprod; 2017 Aug; 32(8):1723-1731. PubMed ID: 28854584
[TBL] [Abstract][Full Text] [Related]
40. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
